![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1363, 2002-01, pp. : 6-6
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Enoxaparin sodium more effective, less costly than UFH
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 388, 2002-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Graded activity no more effective, no less costly in OA
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 528, 2007-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Fondaparinux better than enoxaparin or UFH in ACS
Inpharma, Vol. 1, Iss. 1557, 2006-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Telithromycin less costly than clarithromycin for CAP
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 420, 2003-01 ,pp. :